{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T21:33:36Z","timestamp":1757540016131},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s12094-008-0234-5","type":"journal-article","created":{"date-parts":[[2008,9,2]],"date-time":"2008-09-02T03:04:32Z","timestamp":1220324672000},"page":"462-467","source":"Crossref","is-referenced-by-count":3,"title":["Endocrine therapy of metastatic breast cancer"],"prefix":"10.1007","volume":"10","author":[{"given":"Laura","family":"Rodr\u00edguez Lajusticia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Mart\u00edn Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"L\u00f3pez-Tarruella Cobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,3]]},"reference":[{"key":"234_CR1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2005.07.030","volume":"33","author":"I. Smith","year":"2006","unstructured":"Smith I (2006) Goals of treatment for patients with metastatic breast cancer. Semin Oncol 33:2\u20135","journal-title":"Semin Oncol"},{"key":"234_CR2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/annonc\/mdi816","volume":"16","author":"V.V. Kataja","year":"2005","unstructured":"Kataja VV, Colleoni M, Bergh J (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer. Ann Oncol 16:10\u201312","journal-title":"Ann Oncol"},{"key":"234_CR3","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0959-8049(97)00178-0","volume":"33","author":"J.G. Robertson","year":"1997","unstructured":"Robertson JG, Willsher PC, Cheung KL et al (1997). The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33:1774\u20131779","journal-title":"Eur J Cancer"},{"key":"234_CR4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","volume":"2","author":"G.W. Beatson","year":"1896","unstructured":"Beatson GW (1896) On the treatment of inoperable cases of carcinoma of the mama: suggestions for a new method of treatment with illustrative cases. Lancet 2:104\u2013107, 162\u2013165.","journal-title":"Lancet"},{"key":"234_CR5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0960-0760(92)90210-A","volume":"43","author":"J.G. Klijn","year":"1992","unstructured":"Klijn JG, Berns PM, Bontenbal M et al (1992) Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol 43:211\u2013221","journal-title":"J Steroid Biochem Mol Biol"},{"key":"234_CR6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1634\/theoncologist.9-5-507","volume":"9","author":"T.M. Prowell","year":"2004","unstructured":"Prowell TM, Davidson NE (2004) What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 9:507\u2013517","journal-title":"Oncologist"},{"key":"234_CR7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.1986.4.2.178","volume":"4","author":"J.N. Ingle","year":"1986","unstructured":"Ingle JN, Krook JE, Green SJ et al (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178\u2013185","journal-title":"J Clin Oncol"},{"key":"234_CR8","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1200\/JCO.1986.4.9.1326","volume":"4","author":"R.B. Buchanan","year":"1986","unstructured":"Buchanan RB, Balmey RW, Durrant KR et al (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326\u20131330","journal-title":"J Clin Oncol"},{"key":"234_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1005895813401","volume":"44","author":"C.A. Swaka","year":"1997","unstructured":"Swaka CA, Pritchard KI, Shelly W et al (1997) A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat 44:211\u2013215","journal-title":"Breast Cancer Res Treat"},{"key":"234_CR10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1998.16.3.994","volume":"16","author":"C.W. Taylor","year":"1998","unstructured":"Taylor CW, Green S, Dalton WS et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16:994\u2013999","journal-title":"J Clin Oncol"},{"key":"234_CR11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.annonc.a058837","volume":"5","author":"F. Boccardo","year":"1994","unstructured":"Boccardo F, Rubagotti A, Perotta A et al (1994) Ovarian ablation versus goserelin with or without tamoxifen in pre and perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 5:337\u2013342","journal-title":"Ann Oncol"},{"key":"234_CR12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0959-8049(94)00415-2","volume":"31","author":"W. Jonat","year":"1995","unstructured":"Jonat W, Kauffmann M, Balmey RW et al (1995) A randomized study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre and perimenopausal patients with advanced beast cancer. Eur J Cancer 31:137\u2013142","journal-title":"Eur J Cancer"},{"key":"234_CR13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","volume":"92","author":"J.G. Klijn","year":"2000","unstructured":"Klijn JG, Beex LV, Mauriac L et al (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92:903\u2013911","journal-title":"J Natl Cancer Inst"},{"key":"234_CR14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","volume":"19","author":"J.G. Klijn","year":"2001","unstructured":"Klijn JG, Balmey RW, Boccardo F et al (2001) Combined tamoxifen and luteinising hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343\u2013353","journal-title":"J Clin Oncol"},{"key":"234_CR15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1200\/JCO.1991.9.7.1283","volume":"9","author":"M.C. Sunderland","year":"1991","unstructured":"Sunderland MC, Osborne CK (1991) Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 9:1283\u20131297","journal-title":"J Clin Oncol"},{"key":"234_CR16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1006440802709","volume":"65","author":"A. Milla-Santos","year":"2001","unstructured":"Milla-Santos A, Milla L, Rallo L et al (2001) Phase III randomized trial of toremifene vs tamoxifen in hormonodependent advanced breast cancer. Breast Cancer Res Treat 65:119\u2013124","journal-title":"Breast Cancer Res Treat"},{"key":"234_CR17","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"S.R. Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189\u20132197","journal-title":"JAMA"},{"key":"234_CR18","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"V.G. Vogel","year":"2006","unstructured":"Vogel VG, Constantino JP, Wickerman DL et al (2006) Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727\u20132741","journal-title":"JAMA"},{"key":"234_CR19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(95)91156-1","volume":"345","author":"A. Howell","year":"1995","unstructured":"Howell A, DeFriend D, Robertson J et al (1995) Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29\u201330","journal-title":"Lancet"},{"key":"234_CR20","first-page":"1275","volume":"24","author":"T. Wetanabe","year":"2004","unstructured":"Wetanabe T, Sano M, Ohno S et al (2004) Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study. Anticancer Res 24:1275\u20131280","journal-title":"Anticancer Res"},{"key":"234_CR21","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","volume":"22","author":"A. Howell","year":"2004","unstructured":"Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605\u20131613","journal-title":"J Clin Oncol"},{"key":"234_CR22","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","volume":"20","author":"A. Howell","year":"2002","unstructured":"Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396\u20133403","journal-title":"J Clin Oncol"},{"key":"234_CR23","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1200\/JCO.2002.10.058","volume":"20","author":"C.K. Osborne","year":"2002","unstructured":"Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:2286\u20132295","journal-title":"J Clin Oncol"},{"key":"234_CR24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.11468","volume":"98","author":"J.F. Robertson","year":"2003","unstructured":"Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229\u2013238","journal-title":"Cancer"},{"key":"234_CR25","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1200\/JCO.2005.04.1053","volume":"24","author":"J.N. Inge","year":"2006","unstructured":"Inge JN, Suman VJ, Rowland KM et al (2006) Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24:1052\u20131056","journal-title":"J Clin Oncol"},{"key":"234_CR26","first-page":"8","volume":"100","author":"W.J. Gradishar","year":"2006","unstructured":"Gradishar WJ, Chia S, Piccart-Gebhart MJ et al (2006) Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Breast Cancer Res 100:8\u20139","journal-title":"Breast Cancer Res"},{"key":"234_CR27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2006.08.019","volume":"43","author":"J.F.R. Robertson","year":"2007","unstructured":"Robertson JFR, Semiglazov V, Nemsadze G et al (2007) Effects of fulvestrant 250mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 43: 64\u201370","journal-title":"Eur J Cancer"},{"key":"234_CR28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ejca.2007.11.007","volume":"44","author":"O.E. Young","year":"2008","unstructured":"Young OE, Renshaw L, Macaskill EJ et al (2008) Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 44:391\u2013399","journal-title":"Eur J Cancer"},{"key":"234_CR29","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1002\/1097-0142(20000615)88:12+<3065::AID-CNCR25>3.0.CO;2-P","volume":"12","author":"K.I. Pritchard","year":"2000","unstructured":"Pritchard KI (2000) Current and future directions in medical therapy for breast carcinoma. Cancer 12:3065\u20133072","journal-title":"Cancer"},{"key":"234_CR30","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/djj357","volume":"98","author":"D. Mauri","year":"2006","unstructured":"Mauri D, Pavlidis N, Polyzos NP et al (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer. Meta-analysis. J Natl Cancer Inst 98:1285\u20131291","journal-title":"Meta-analysis. J Natl Cancer Inst"},{"key":"234_CR31","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","volume":"18","author":"M. Kaufmann","year":"2000","unstructured":"Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double blind trial. J Clin Oncol 18: 1399\u20131411","journal-title":"J Clin Oncol"},{"key":"234_CR32","first-page":"730","volume":"79","author":"A.U. Buzdar","year":"1997","unstructured":"Buzdar AU, Jones SE, Vogel CL et al (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79:730\u2013739","journal-title":"Arimidex Study Group. Cancer"},{"key":"234_CR33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0959-8049(95)00014-3","volume":"32","author":"W. Jonat","year":"1996","unstructured":"Jonat W, Howell A, Blomquist C et al (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32:404\u2013412","journal-title":"Eur J Cancer"},{"key":"234_CR34","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","volume":"18","author":"J. Bonneterre","year":"2000","unstructured":"Bonneterre J, Thurlimann B, Robertson JF et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 18:3748\u20133757","journal-title":"J Clin Oncol"},{"key":"234_CR35","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","volume":"18","author":"J.M. Nabholtz","year":"2000","unstructured":"Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758\u20133767","journal-title":"Arimidex Study Group. J Clin Oncol"},{"key":"234_CR36","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","volume":"92","author":"J. Bonnetere","year":"2002","unstructured":"Bonnetere J, Buzdar A, Nabholtz JM et al (2002) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247\u20132258","journal-title":"Cancer"},{"key":"234_CR37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10549-007-9527-6","volume":"105","author":"H.T. Mouridsen","year":"2007","unstructured":"Mouridsen HT (2007) Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 105:19\u201329","journal-title":"Breast Cancer Res Treat"},{"key":"234_CR38","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/S0959-8049(03)00630-0","volume":"39","author":"C. Rose","year":"2003","unstructured":"Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318\u20132327","journal-title":"Eur J Cancer"},{"key":"234_CR39","doi-asserted-by":"crossref","first-page":"515A","DOI":"10.1200\/jco.2004.22.14_suppl.515","volume":"22","author":"R. Paridaens","year":"2004","unstructured":"Paridaens R, Therasse P, Dirix L et al (2004) First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients. A randomized phase III trial of the EORTC Breast Group. ASCO Annual Meeting Proceedings. J Clin Oncol 22:515A","journal-title":"J Clin Oncol"},{"key":"234_CR40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000090985","volume":"69","author":"G. Bertelli","year":"2005","unstructured":"Bertelli G, Garona O, Merlano M et al (2005) Sequential treatment with exemestane and non-steroideal aromatase inhibitors in advanced breast cancer. Oncology 69:471\u2013477","journal-title":"Oncology"},{"key":"234_CR41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bjc.1990.356","volume":"62","author":"R.C. Stein","year":"1990","unstructured":"Stein RC, Dowsett M, Hedley A et al (1990) The clinical and endocrine effects of 4-hydroxyadndrostendione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62:679\u2013683","journal-title":"Br J Cancer"},{"key":"234_CR42","first-page":"2261","volume":"19","author":"L. Celio","year":"1999","unstructured":"Celio L, Martinetti A, Ferrari L (1999) Premenopausal breast cancer patients treated with a gonadotrophin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 19:2261\u20132268","journal-title":"Anticancer Res"},{"key":"234_CR43","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.bjc.6601557","volume":"90","author":"D.P. Forward","year":"2004","unstructured":"Forward DP, Cheung KL, Jackson L et al (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590\u2013594","journal-title":"Br J Cancer"},{"key":"234_CR44","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1994.12.8.1630","volume":"12","author":"H.B. Muss","year":"1994","unstructured":"Muss HB, Case LD, Alkins JN et al (1994) Tamoxifen versus high dose medroxiprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 12:1630\u20131638","journal-title":"J Clin Oncol"},{"key":"234_CR45","first-page":"172","volume":"1","author":"G. Wolf","year":"1978","unstructured":"Wolf G, Rieche K (1978) Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testosterone-drostanolone. Onkologie 1:172\u2013174","journal-title":"Controlled clinical study: nandrolone-testosterone-drostanolone. Onkologie"},{"key":"234_CR46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1677\/erc.1.01273","volume":"13","author":"S. Massarweh","year":"2006","unstructured":"Massarweh S, Schiff R (2006) Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor\/growth factor signaling crosstalk. Endocr Relat Cancer 13:15\u201324","journal-title":"Endocr Relat Cancer"},{"key":"234_CR47","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.2005.10.036","volume":"23","author":"C.K. Osborne","year":"2005","unstructured":"Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616\u20131622","journal-title":"J Clin Oncol"},{"key":"234_CR48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-006-9307-8","volume":"102","author":"P.K. Marcom","year":"2007","unstructured":"Marcom PK, Isaacs C, Harris L et al (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43\u201349","journal-title":"Breast Cancer Res Treat"},{"key":"234_CR49","unstructured":"Kaufman B, Mackey J, Clemens M et al (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). In: Proceedings from 31st ESMO Congress, Istanbul 2006. LBA2"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-008-0234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-008-0234-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-008-0234-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:50:41Z","timestamp":1559447441000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-008-0234-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["234"],"URL":"https:\/\/doi.org\/10.1007\/s12094-008-0234-5","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}